Industry, FDA Agree On Draft User Fee Commitment Letter
This article was originally published in The Gray Sheet
Executive Summary
Draft commitment and legislative language come one month after agreement “in principle” on MDUFA III reauthorization.
You may also be interested in...
PDUFA First: Fees To Support US FDA Device Center Staff
To enhance combination product reviews, drug-fee revenue will pay for related positions in the agency's Center for Devices and Radiological Health.
PDUFA First: Fees To Support Device Center Staff
To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.
FDA Proposes To Exempt Dozens Of Devices From 510(k) Requirements
FDA plans to exempt an array of class II and class I medical devices from premarket submission requirements because the devices are sufficiently well understood and do not present risks that require premarket notification review to assure their safety and effectiveness.